Intravenous Immunoglobulin (Ivig) Market Is Expected To Grow At Significant Growth Rate Of 7.50 % CAGR During 2022-2030

August 2022, Market Research Future has published a Report on the Global Global Intravenous Immunoglobulin (IVIg) Market.

Intravenous Immunoglobulin Market Highlights

The global Intravenous Immunoglobulin (IVIg) market has been evaluated as moderately growing market and it is expected that the market will continue to grow similarly in the near future. The demand for new products and therapy is growing continuously. The market for Intravenous Immunoglobulin (IVIg) was around USD 20.96 Billion and is expected to grow at a CAGR of 7.50% by 2030.

There are plenty of large and small market players which operate in this market: ABEONA THERAPEUTICS (US), Baxter (US), BDI Pharma (US), Biotest AG.(Germany),, China Biologic Products, Inc. (China), CSL Behring (US), Grifols Inc. (Spain), Kedrion S.p.A (us), Octapharma (Switzerland), Shire (Republic of Ireland), AND others.

Biotest AG. Was found in 1946 and based in Germany. Biotest AG is one of the key players in the market. This company employed about 2,527 people throughout the world and total revenue of the company is US$ 622.7million in 2016. In May 2017, Biotest AG sold their US therapy business to ADMA Biologics, Inc. and received specified current products and a rights related to first order for distribution of upcoming products of ADMA Biologics, Inc. in Europe and selected parts of Asia and middle East.

Octapharma was founded in 1983. Octapharma is Switzerland based one of the largest human protein product manufacture in the world. This company is in development and production of human proteins for human plasma and human cell line. The total revenue of the company in 2016 was US$ 1.8 billion. Company has more than 7,000 employees throughout the globe. In 2016, Octopharma Plasma, Inc.’s Testing Laboratory received approval from U.S. Food and Drug Administration (FDA).

The Republic of Ireland based company Shire was founded in 1986. Shire is focusing on R&D and production for rare diseases. The total revenue of Shire in 2016 was US4 11.6 billion and was generated US$ 1,516 million from immunology sales. The products of Shire are available in more than 100 countries and has about 23,900 employee strength.

All the major companies are investing money in R&D that will show positive impact on market growth.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Intravenous Immunoglobulin Market Research Report

Regional Analysis:

Considering the global scenario of the market, North America was holding largest market share in global IVIg market in 2016. While the European market, especially Western Europe is growing and second largest market for Global IVIg. Asia-Pacific will be fastest growing market for IVIg during the forecasted period. Middle East and Africa is expected to grow at steady pace during the forecast period. 

Segmentation:

Intravenous Immunoglobulin (IVIg) Market has been segmented on the basis of type which comprise Plaque psoriasis, Scalp psoriasis, Nail psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis, Erythrodermic psoriasis and others. Plaque psoriasis is most common type and about 80% of the cases are plaque psoriasis.  On the basis of treatment type it segmented into Topical corticosteroids, Vitamin D analogues (Calcipotriene, Calcitriol), Anthralin, Topical retinoids (Retinol, Tretinoin (retinoic acid / retin-A /Steiva-A), Adapalene (Differin), Tazarotene), Calcineurin inhibitors (tacrolimus (Prograf), pimecrolimus (Elidel)), Salicylic acid, Coal tar, Moisturizers, and Others. Vitamin D analogs such as Calcipotriene and Calcitriol very helpful and helps to slow skin cell growth. Topical retinoids like are Retinol, Tretinoin (retinoic acid / retin-A /Steiva-A), Adapalene (Differin), Tazarotene are vitamin A derivatives that helps to reduce inflammation.